Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

Abstract

Long-term enzyme replacement therapy with agalsidase alfa is safe and may slow the progressive decline in renal function that was commonly observed in adult males with Fabry disease.